Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims:
advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags:
FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns:
homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations:
specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…
NUCALA (GSK)
(https://nucala.com) 📸 Data Snapshot: May 30, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Discover a Treatment Option | NUCALA (mepolizumab) (https://nucala.com)
Title
Discover a Treatment Option | NUCALA (mepolizumab)
Meta
Learn more about NUCALA (mepolizumab), a targeted biologic treatment approved for five different conditions.
H1 LET’S GET TO IT WITH NUCALA
H2 Start here:
H2 Approved Use
H3 Talk to your doctor to see if adding NUCALA is right for you.
H3 Approved Uses & Safety Info
H3 Approved Uses
H3 Important Safety Information
H3 Approved Uses
H3 Important Safety Information
H5 Eosinophilic Chronic Obstructive Pulmonary Disease (Adults)
H5 Severe Eosinophilic Asthma (Ages 6+) disponible en español
H5 Chronic Rhinosinusitis with Nasal Polyps (Adults)
H5 Eosinophilic Granulomatosis with Polyangiitis (Adults)
H5 Hypereosinophilic Syndrome (Ages 12+)
H5 You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report negative side effects to GSK at gsk.public.reportum.com or 1-888-825-5249.
NAV_HEADER_HEADING_REPEATED_BODY Patient Support Program | NUCALA (mepolizumab) (https://nucala.com/support-resources/patient-support-program/)
Title
Patient Support Program | NUCALA (mepolizumab)
Meta
Discover a patient support program that can help you understand the medication coverage process, identify cost assistance options, and connect with a Patient Navigator.
H1 FOR PATIENTS PRESCRIBED NUCALA…
H3 Talk to your doctor to see if adding NUCALA is right for you.
H3 Approved Uses & Safety Info
H3 Approved Uses
H3 Important Safety Information
H3 Approved Uses
H3 Important Safety Information
H5 You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report negative side effects to GSK at gsk.public.reportum.com or 1-888-825-5249.
HEADER_HEADING_REPEATED_BODY Approved for COPD | NUCALA (mepolizumab) (https://nucala.com/copd/)
Title
Approved for COPD | NUCALA (mepolizumab)
Meta
Struggling with COPD symptoms? NUCALA (mepolizumab) is an add-on, prescription treatment for adults with uncontrolled eosinophilic COPD. Not for sudden breathing problems.
H1 IS IT TIME TO TREAT YOUR COPD DIFFERENTLY?
H2 What could adding NUCALA mean for you?
H2 Once a month.† At home. On YOUR time.
H2 Find out if NUCALA is right for your kind of COPD.
H3 Talk to your doctor to see if adding NUCALA is right for you.
H3 Approved Use & Safety Info
H3 Approved Use
H3 Important Safety Information
H3 Approved Use
H3 Important Safety Information
H5 You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report negative side effects to GSK at gsk.public.reportum.com or 1-888-825-5249.
HEADER_HEADING_REPEATED_BODY Severe Eosinophilic Asthma Treatment | NUCALA (mepolizumab) (https://nucala.com/severe-eosinophilic-asthma/)
Title
Severe Eosinophilic Asthma Treatment | NUCALA (mepolizumab)
Meta
Learn more about NUCALA (mepolizumab), an add-on, prescription treatment for patients aged 6+ with severe eosinophilic asthma. Not for sudden breathing problems.
H1 READY TO STAND UP TO YOUR SEVERE ASTHMA?
H2 Let’s get to it with NUCALA. Think:
H2 Once a month.* At home. On YOUR time.
H2 NUCALA has 9+ years in market.
H3 LESS asthma attacks
H3 LESS need for oral steroids
H3 LESS asthma-related hospital visits
H3 Angie lives her life with NUCALA
H3 Talk to your doctor to see if adding NUCALA is right for you.
H3 Approved Use & Safety Info
H3 Approved Use
H3 Important Safety Information
H3 Approved Use
H3 Important Safety Information
H5 You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report negative side effects to GSK at gsk.public.reportum.com or 1-888-825-5249.
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://nucala.com) Discover a Treatment Option | NUCALA (mepolizumab)
You are about to leave a GSK websiteYou are about to leave a GSK website. By clicking this link, you will be taken to a website that is independent from GSK. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. GO BACKCONTINUE [H1] LET’S GET TO IT WITH NUCALA NUCALA is a targeted biologic treatment, approved for 5 conditions. Click on yours below to see how NUCALA might help. Autoinjector for patients 12+. [H2] Start here: [H5] Eosinophilic Chronic Obstructive Pulmonary Disease (Adults) [H5] Severe Eosinophilic Asthma (Ages 6+) disponible en español [H5] Chronic Rhinosinusitis with Nasal Polyps (Adults) [H5] Eosinophilic Granulomatosis with Polyangiitis (Adults) [H5] Hypereosinophilic Syndrome (Ages 12+) [H2] Approved Use NUCALA is approved for the following: Chronic Obstructive Pulmonary Disease (COPD)—NUCALA is an add-on, prescription maintenance treatment of eosinophilic COPD in adults whose disease is not controlled. NUCALA is not used to treat sudden breathing problems. Severe Eosinophilic Asthma (SEA)—NUCALA is an add-on, prescription maintenance treatment for patients 6 and older with SEA. NUCALA is not used to treat sudden breathing problems. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)—NUCALA is a prescription medicine for add-on maintenance treatment of CRSwNP in adults whose disease is not controlled with nasal corticosteroids. Eosinophilic Granulomatosis with Polyangiitis (EGPA)—NUCALA is a prescription medicine for the treatment of adults with EGPA. Hypereosinophilic Syndrome (HES)—NUCALA is a prescription medicine for the treatment of people 12 years of age and older with HES for 6 months or more. [IMG: Get to it] [H2] Looking for support? Once you've been prescribed NUCALA, Together with NUCALA provides resources with information on cost, coverage, and patient support. EXPLORE PATIENT SUPPORT [H3] Talk to your doctor to see if adding NUCALA is right for you. [H3] Approved Uses & Safety Info [H3] Approved Uses [H3] Important Safety Information [H3] Approved Uses NUCALA is a prescription medicine for the: add-on maintenance treatment of patients 6 and older with severe eosinophilic asthma. NUCALA is not used to treat sudden breathing problems. add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults whose disease is not controlled with nasal corticosteroids. add-on maintenance treatment of eosinophilic chronic obstructive pulmonary disease (COPD) in adults whose disease is not controlled. NUCALA is not used to treat sudden breathing problems. treatment of adults with eosinophilic granulomatosis with polyangiitis (EGPA). treatment of people 12 years of age and older with hypereosinophilic syndrome (HES) for 6 months or more. [H3] Important Safety Information Do not use NUCALA if you are allergic to mepolizumab or any of the ingredients in NUCALA. Do not use to treat sudden breathing problems. NUCALA can cause serious side effects, including: allergic (hypersensitivity) reactions, including anaphylaxis. Serious allergic reactions can happen after you get your NUCALA injection. Allergic reactions can sometimes happen hours or days after you get a dose of NUCALA. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction: swelling of your face, mouth, and tongue breathing problems fainting, dizziness, feeling lightheaded (low blood pressure) rash hives herpes zoster infections that can cause shingles have happened in people who received NUCALA. Before receiving NUCALA, tell your healthcare provider about all of your medical conditions, including if you: are taking oral or inhaled corticosteroid medicines. Do not stop taking your other medicines, including your corticosteroid medicines, unless instructed by your healthcare provider because this may cause other symptoms to come back. have a parasitic (helminth) infection. are pregnant or plan to become pregnant. It is not known if NUCALA may harm your unborn baby. are breastfeeding or plan to breastfeed. You and your healthcare provider should decide if you will use NUCALA and breastfeed. You should not do both without talking with your healthcare provider first. are taking prescription and over-the-counter medicines, vitamins, and herbal supplements. The most common side effects of NUCALA include: headache, injection site reactions (pain, redness, swelling, itching, or a burning feeling at the injection site), back pain, and tiredness (fatigue). Mouth/throat pain and joint pain have been reported with CRSwNP. Diarrhea and cough have been reported with COPD. Please see full Prescribing Information for NUCALA. [H5] You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report negative side effects to GSK at gsk.public.reportum.com or 1-888-825-5249. [IMG: Visit GSK Help Center website] Explore the GSK Help Center website to find customer service support and contact information. Contact Us [IMG: Together with NUCALA logo] If you have questions about how to access or pay for your GSK medication, visit togetherwithnucala.com or call 1-844-Call-TwGSK (1-844-475-3678).
5359 chars
SUB-PAGE (https://nucala.com/support-resources/patient-support-program/) Patient Support Program | NUCALA (mepolizumab)
You are about to leave a GSK websiteYou are about to leave a GSK website. By clicking this link, you will be taken to a website that is independent from GSK. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. GO BACKCONTINUEPATIENT SUPPORT PROGRAM [H1] FOR PATIENTS PRESCRIBED NUCALA… Together with NUCALA is more than a program—it’s our promise to try to understand your needs, listen to what matters most to you, and create meaningful connections along the way. EXPLORE TOGETHER WITH NUCALA [IMG: Here] [H2] Once your doctor has prescribed NUCALA... We can provide resources with information on cost, coverage, and patient support. [H2] What you can expect from Together with NUCALA: [H3] Coverage Support We’ll check your insurance coverage and help you understand your benefits.* [H3] Cost Support We're here to let you know about the options for help paying for NUCALA if you are eligible. [H3] Patient Support Your Patient Navigator† is at the heart of our program, offering education, resources, and support. *The information provided by Together with NUCALA is not a guarantee of coverage or payment. †The Patient Navigator does not provide medical advice and is not a part of your doctor’s care team. Please ask your doctor any questions that you might have about your disease and treatment with NUCALA. [H2] Only interested in copay support? We understand that cost matters. We offer copay assistance for eligible commercially insured patients to help with your out-of-pocket cost. GET STARTED [H3] Still have questions about NUCALA? Find answers to Frequently Asked Questions. [H3] Talk to your doctor to see if adding NUCALA is right for you. [H3] Approved Uses & Safety Info [H3] Approved Uses [H3] Important Safety Information [H3] Approved Uses NUCALA is a prescription medicine for the: add-on maintenance treatment of patients 6 and older with severe eosinophilic asthma. NUCALA is not used to treat sudden breathing problems. add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults whose disease is not controlled with nasal corticosteroids. add-on maintenance treatment of eosinophilic chronic obstructive pulmonary disease (COPD) in adults whose disease is not controlled. NUCALA is not used to treat sudden breathing problems. treatment of adults with eosinophilic granulomatosis with polyangiitis (EGPA). treatment of people 12 years of age and older with hypereosinophilic syndrome (HES) for 6 months or more. [H3] Important Safety Information Do not use NUCALA if you are allergic to mepolizumab or any of the ingredients in NUCALA. Do not use to treat sudden breathing problems. NUCALA can cause serious side effects, including: allergic (hypersensitivity) reactions, including anaphylaxis. Serious allergic reactions can happen after you get your NUCALA injection. Allergic reactions can sometimes happen hours or days after you get a dose of NUCALA. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction: swelling of your face, mouth, and tongue breathing problems fainting, dizziness, feeling lightheaded (low blood pressure) rash hives herpes zoster infections that can cause shingles have happened in people who received NUCALA. Before receiving NUCALA, tell your healthcare provider about all of your medical conditions, including if you: are taking oral or inhaled corticosteroid medicines. Do not stop taking your other medicines, including your corticosteroid medicines, unless instructed by your healthcare provider because this may cause other symptoms to come back. have a parasitic (helminth) infection. are pregnant or plan to become pregnant. It is not known if NUCALA may harm your unborn baby. are breastfeeding or plan to breastfeed. You and your healthcare provider should decide if you will use NUCALA and breastfeed. You should not do both without talking with your healthcare provider first. are taking prescription and over-the-counter medicines, vitamins, and herbal supplements. The most common side effects of NUCALA include: headache, injection site reactions (pain, redness, swelling, itching, or a burning feeling at the injection site), back pain, and tiredness (fatigue). Mouth/throat pain and joint pain have been reported with CRSwNP. Diarrhea and cough have been reported with COPD. Please see full Prescribing Information for NUCALA. [H5] You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report negative side effects to GSK at gsk.public.reportum.com or 1-888-825-5249. [IMG: Visit GSK Help Center website] Explore the GSK Help Center website to find customer service support and contact information. Contact Us [IMG: Together with NUCALA logo] If you have questions about how to access or pay for your GSK medication, visit togetherwithnucala.com or call 1-844-Call-TwGSK (1-844-475-3678).
5106 chars
SUB-PAGE (https://nucala.com/copd/) Approved for COPD | NUCALA (mepolizumab)
You are about to leave a GSK websiteYou are about to leave a GSK website. By clicking this link, you will be taken to a website that is independent from GSK. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. GO BACKCONTINUE [H1] IS IT TIME TO TREAT YOUR COPD DIFFERENTLY? NUCALA is an add-on, prescription maintenance treatment of eosinophilic chronic obstructive pulmonary disease (COPD) in adults whose disease is not controlled. NUCALA is not used to treat sudden breathing problems. WHAT IS UNCONTROLLED COPD? [H2] What could adding NUCALA mean for you? [H3] FEWER flare-ups Results may vary. [H3] FEWER hospital visits due to flare-ups* Results may vary. *Based on the limits of the study, this result is descriptive. [H3] FEWER total doses per year vs other COPD biologic† No comparative efficacy or safety conclusions can be drawn from this information. †Every 4 weeks vs every other week. [IMG: NUCALA targets inflammation] [H2] NUCALA is a different kind of COPD treatment. It’s not an inhaler or a steroid. NUCALA is the first and only once-monthly† biologic for eosinophilic COPD. It works by targeting inflammation and reducing eosinophils—which are possible causes of COPD flare-ups.‡ What is a biologic? Biologics are treatments derived from natural sources and are able to help target certain immune cells, such as eosinophils in COPD, which can contribute to inflammation. HOW NUCALA WORKS †Every 4 weeks. ‡It is not fully understood how NUCALA works. [H2] Once a month.† At home. On YOUR time. When it comes to your COPD treatment, convenience is key. You can take the NUCALA Autoinjector at home, just once a month, or at your specialist’s office. Want to see how easy§ the Autoinjector could be for you to use? HOW TO INJECT NUCALA †Every 4 weeks. §Severe asthma patients rated the Autoinjector as easy-to-use after training. See full Instructions for Use. [IMG: What] [H2] Find out if NUCALA is right for your kind of COPD. Ask your specialist about simple blood testing to measure eosinophil levels. [H3] Questions about paying for NUCALA? When it comes to paying for NUCALA, there may be options available to you. EXPLORE SUPPORT [H3] Looking for support? Once you've been prescribed NUCALA, Together with NUCALA provides resources with information on cost, coverage, and patient support. EXPLORE PATIENT SUPPORT [H2] Want to learn more about NUCALA? Check out the brochure for more info and tips on talking to your specialist. DOWNLOAD BROCHURE DESCARGAR EN ESPAÑOL [H3] Talk to your doctor to see if adding NUCALA is right for you. [H3] Approved Use & Safety Info [H3] Approved Use [H3] Important Safety Information [H3] Approved Use NUCALA is an add-on, prescription maintenance treatment of eosinophilic chronic obstructive pulmonary disease (COPD) in adults whose disease is not controlled. NUCALA is not used to treat sudden breathing problems. [H3] Important Safety Information Do not use NUCALA if you are allergic to mepolizumab or any of the ingredients in NUCALA. Do not use to treat sudden breathing problems. NUCALA can cause serious side effects, including: allergic (hypersensitivity) reactions, including anaphylaxis. Serious allergic reactions can happen after you get your NUCALA injection. Allergic reactions can sometimes happen hours or days after you get a dose of NUCALA. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction: swelling of your face, mouth, and tongue breathing problems fainting, dizziness, feeling lightheaded (low blood pressure) rash hives herpes zoster infections that can cause shingles have happened in people who received NUCALA. Before receiving NUCALA, tell your healthcare provider about all of your medical conditions, including if you: are taking oral or inhaled corticosteroid medicines. Do not stop taking your other medicines, including your corticosteroid medicines, unless instructed by your healthcare provider because this may cause other symptoms to come back. have a parasitic (helminth) infection. are pregnant or plan to become pregnant. It is not known if NUCALA may harm your unborn baby. are breastfeeding or plan to breastfeed. You and your healthcare provider should decide if you will use NUCALA and breastfeed. You should not do both without talking with your healthcare provider first. are taking prescription and over-the-counter medicines, vitamins, and herbal supplements. The most common side effects of NUCALA include: headache, injection site reactions (pain, redness, swelling, itching, or a burning feeling at the injection site), back pain, and tiredness (fatigue). Diarrhea and cough have been reported with COPD. Please see full Prescribing Information for NUCALA. [H5] You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report negative side effects to GSK at gsk.public.reportum.com or 1-888-825-5249. [IMG: Visit GSK Help Center website] Explore the GSK Help Center website to find customer service support and contact information. Contact Us [IMG: Together with NUCALA logo] If you have questions about how to access or pay for your GSK medication, visit togetherwithnucala.com or call 1-844-Call-TwGSK (1-844-475-3678).
5459 chars
SUB-PAGE (https://nucala.com/severe-eosinophilic-asthma/) Severe Eosinophilic Asthma Treatment | NUCALA (mepolizumab)
You are about to leave a GSK websiteYou are about to leave a GSK website. By clicking this link, you will be taken to a website that is independent from GSK. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. GO BACKCONTINUE [H1] READY TO STAND UP TO YOUR SEVERE ASTHMA? NUCALA is an add-on, prescription maintenance treatment for patients 6 and older with severe eosinophilic asthma. NUCALA is not used to treat sudden breathing problems. results with nucala [H2] Let’s get to it with NUCALA. Think: [H3] LESS asthma attacks [H3] LESS need for oral steroids [H3] LESS asthma-related hospital visits Results may vary. [H2] Once a month.* At home. On YOUR time. When it comes to your treatment, convenience is key. The NUCALA Autoinjector can be taken at home–just once a month. Want to see how easy† the Autoinjector could be for you to use? HOW TO INJECT NUCALA Autoinjector for patients 12+. *Every 4 weeks. †Severe asthma patients rated the Autoinjector as easy-to-use after training. See full Instructions for Use. [H2] NUCALA has 9+ years in market. [IMG: Get Real: NUCALA patient Angie] [H3] Angie lives her life with NUCALA When her symptoms started getting worse, Angie decided it was time to take action. She learned her asthma was different. And NUCALA helped her live her life on her terms. WATCH ANGIE’S EXPERIENCE [IMG: Get to it] [H3] Looking for support? Once you've been prescribed NUCALA, Together with NUCALA provides resources with information on cost, coverage, and patient support. EXPLORE PATIENT SUPPORT [H2] Want to learn more about NUCALA? Check out the brochure for more info and tips on talking to your specialist. DOWNLOAD BROCHURE [H3] Talk to your doctor to see if adding NUCALA is right for you. [H3] Approved Use & Safety Info [H3] Approved Use [H3] Important Safety Information [H3] Approved Use NUCALA is an add-on, prescription maintenance treatment for patients 6 and older with severe eosinophilic asthma. NUCALA is not used to treat sudden breathing problems. [H3] Important Safety Information Do not use NUCALA if you are allergic to mepolizumab or any of the ingredients in NUCALA. Do not use to treat sudden breathing problems. NUCALA can cause serious side effects, including: allergic (hypersensitivity) reactions, including anaphylaxis. Serious allergic reactions can happen after you get your NUCALA injection. Allergic reactions can sometimes happen hours or days after you get a dose of NUCALA. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction: swelling of your face, mouth, and tongue breathing problems fainting, dizziness, feeling lightheaded (low blood pressure) rash hives herpes zoster infections that can cause shingles have happened in people who received NUCALA. Before receiving NUCALA, tell your healthcare provider about all of your medical conditions, including if you: are taking oral or inhaled corticosteroid medicines. Do not stop taking your other asthma medicines, including your corticosteroid medicines, unless instructed by your healthcare provider because this may cause other symptoms to come back. have a parasitic (helminth) infection. are pregnant or plan to become pregnant. It is not known if NUCALA may harm your unborn baby. are breastfeeding or plan to breastfeed. You and your healthcare provider should decide if you will use NUCALA and breastfeed. You should not do both without talking with your healthcare provider first. are taking prescription and over-the-counter medicines, vitamins, and herbal supplements. The most common side effects of NUCALA include: headache, injection site reactions (pain, redness, swelling, itching, or a burning feeling at the injection site), back pain, and tiredness (fatigue). Please see full Prescribing Information for NUCALA. [H5] You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report negative side effects to GSK at gsk.public.reportum.com or 1-888-825-5249. [IMG: Visit GSK Help Center website] Explore the GSK Help Center website to find customer service support and contact information. Contact Us [IMG: Together with NUCALA logo] If you have questions about how to access or pay for your GSK medication, visit togetherwithnucala.com or call 1-844-Call-TwGSK (1-844-475-3678).
4511 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
26Review mentions (all pages)
8External proof links (all pages)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 14 | 2 |
| /support-resources/patient-support-program/ | 4 | 2 |
| /copd/ | 4 | 2 |
| /severe-eosinophilic-asthma/ | 4 | 2 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage — no schema detected (entity gap)
/support-resources/patient-support-program/ — no schema detected (entity gap)
/copd/ — no schema detected (entity gap)
/severe-eosinophilic-asthma/ — no schema detected (entity gap)
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Information Density
0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence
0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof
0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint
0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority
0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score
0 / 100
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Information Density
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Semantic Alignment
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Trust & Proof
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Commodity Fingerprint
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Identity & Authority
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS
Based on 784 businesses audited.
✓ Less BS than average
NUCALA (GSK) has 5.7 points less BS than the average for Medical Devices, Pharma & Biotech.
BS Detector
Medical Devices, Pharma & Biotech BS: NUCALA (GSK) (nucala.com)
https://nucala.com
📍 Industry: Medical Devices, Pharma & Biotech
35
BS / 100
NUCALA.com is a textbook example of high-substance pharma content wrapped in low-substance lifestyle marketing. The bullshit is purely cosmetic, designed to make a complex biologic feel ‘easy,’ while the core clinical claims are heavily fortified by regulatory necessity and pharmacovigilance requirements.
Info Density
Power-words vs. Substance ratio.
12
40% BS
Semantic Coherence
Homepage promise vs. Sub-page reality.
2
10% BS
Trust & Proof
Verifiable evidence vs. Trust Theatre.
7
35% BS
Commodity Fingerprint
Detection of industry clichés/templates.
7
47% BS
Identity & Authority
Expert verifiability & Schema depth.
7
47% BS
Implement Organization and Drug schema to provide technical authority to the brand and its indications. Replace generic ‘results may vary’ footers with direct links to the specific clinical trial data on ClinicalTrials.gov that supports the ‘FEWER flare-ups’ claim. Diversify patient testimonials with actual clinical outcome summaries to move beyond the ‘lifestyle’ marketing trope. Streamline the redundant heading hierarchy to prevent the repeating [H3] Important Safety Information blocks from drowning out the unique therapeutic value propositions.
The site perfectly matches the Medical/Pharma category, utilizing technical descriptors like ‘targeted biologic’, ‘mepolizumab’, and ‘eosinophilic’. The presence of mandatory ‘Important Safety Information’ (ISI) and FDA reporting links confirms its alignment with heavily regulated biotechnology standards.
“The score of 35 is driven primarily by the lack of structured data and the high volume of lifestyle marketing clichés used to bridge the gap between technical science and patient ease-of-use. It remains in the Low BS category because of the high substance mandated by pharmaceutical regulations and the perfect alignment between homepage signals and sub-page delivery.”
Verified Analysis Date: May 30, 2026
© 1EuroSEO Independent Evaluator — Non-Sponsored Result
Analysis Disclosure & Source Attribution
This training module utilizes a snapshot of public data from NUCALA (GSK), captured on May 30, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to NUCALA (GSK): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://nucala.com to view the most current version of its content and learn from the source what this company is about and what it offers.